S&P 500 7,573.01 -0.48% NASDAQ 26,895.40 -0.73% DOW 50,888.41 -0.82% R2K 2,897.28 -1.18% VIX 16.01 +1.52%
Next Bullish Trade
INSM Insmed Incorporated NMS
$103.86 +0.13 (+0.13%)
Pullback · -1.58σ
+ Compare Set alert Open in Sniper

Price chart

Overlay: Click earnings ▲ markers for day-move details

Loading 1Y daily…

Financial overlay · last 12 quarters

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $0.3B $-0.2B $-0.2B $-0.2B -53.5% -65.5%
2025-12-31 $0.3B $-0.3B $-0.2B $-0.3B -124.5% -94.6%
2025-09-30 $0.1B $-0.4B $-0.3B $-0.2B -260.0% -183.6%
2025-06-30 $0.1B $-0.3B $-0.3B $-0.2B -299.5% -236.4%
2025-03-31 $0.1B $-0.3B $-0.2B $-0.3B -276.4% -247.6%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Earnings replay · last 20 reports

DateEPS actual EPS estSurprise
2026-05-07 -0.76 -1.00 +23.9%
2026-02-19 -1.54 -1.17 -31.9%
2025-10-30 -1.75 -1.37 -27.8%
2025-08-07 -1.70 -1.31 -29.6%
2025-05-08 -1.42 -1.36 -4.2%
2025-02-20 -1.32 -1.17 -12.3%
2024-10-31 -1.27 -1.21 -4.9%
2024-08-08 -1.94 -1.23 -58.2%
2024-05-09 -1.06 -1.20 +11.5%
2024-02-22 -1.28 -1.13 -13.3%
2023-10-26 -1.11 -1.11 +0.2%
2023-08-03 -1.78 -1.12 -58.9%
2023-05-04 -1.17 -1.10 -6.4%
2023-02-23 -1.21 -1.02 -18.2%
2022-10-27 -1.09 -0.87 -24.9%
2022-08-04 -0.80 -0.89 +10.6%
2022-05-05 -0.80 -0.87 +8.1%
2022-02-17 -0.95 -0.86 -10.2%
2021-10-28 -0.96 -0.78 -23.1%
2021-08-05 -0.91 -0.88 -2.7%

Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).

Peer comparison · Healthcare

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
INSM ★ $23B — 257.1 27.5 -23.2 31.9 81.8% 229.6% — -2.69%
LLY $971B 38.6 24.5 13.4 27.3 31.2 82.8% 55.5% 169.9% 0.94%
UNH $346B 28.8 18.3 0.8 18.5 3.5 18.8% 2.0% 0.7% 5.11%
JNJ $538B 25.9 17.6 5.6 16.6 6.6 68.0% 9.9% -52.9% 2.32%
MRK $284B 32.4 12.0 4.3 11.2 6.2 76.7% 4.9% — 4.95%
ABBV $386B 106.6 13.5 6.1 14.8 -58.0 72.0% 12.4% -46.2% 5.39%
PFE $145B 19.4 9.0 2.3 7.8 1.6 74.8% 5.4% -10.1% 8.55%
TMO $176B 26.1 17.4 3.9 19.4 3.3 40.9% 6.2% 11.3% 3.13%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Top institutional holders

Top-10 concentration: 53.5%

HolderShares% out
JPMORGAN CHASE & CO 24,150,499 11.14%
Darwin Global Management, Ltd. 16,805,184 7.75%
Blackrock Inc. 16,678,146 7.69%
FMR, LLC 13,160,167 6.07%
Vanguard Portfolio Management LLC 10,371,802 4.79%
Vanguard Capital Management LLC 9,642,131 4.45%
Baker Bros. Advisors, LP 7,421,111 3.42%
Artisan Partners Limited Partnership 6,527,301 3.01%
Shaw D.E. & Co., Inc. 5,625,825 2.60%
Capital International Investors 5,595,194 2.58%

Insider activity · 90d

No insider trades for INSM in last 90d.

Analyst estimates

yfinance
Low
$140.0
Mean
$200.0
High
$243.0
Analysts
21

Consensus: strong_buy (mean 1.22727). Distribution requires FINNHUB_API_KEY.

SEC filings

FormFiled DescriptionAction
4 2026-05-22 FORM 4 view ·
4 2026-05-20 FORM 4 view ·
4 2026-05-15 FORM 4 view ·
4 2026-05-15 FORM 4 view ·
4 2026-05-15 FORM 4 view ·
4 2026-05-15 FORM 4 view ·
4 2026-05-15 FORM 4 view ·
4 2026-05-15 FORM 4 view ·
4 2026-05-15 FORM 4 view ·
4 2026-05-15 FORM 4 view ·
4 2026-05-15 FORM 4 view ·
4 2026-05-15 FORM 4 view ·
4 2026-05-15 FORM 4 view ·
8-K 2026-05-15 8-K view ·
4 2026-05-13 FORM 4 view ·
8-K 2026-05-07 8-K view ·
10-Q 2026-05-07 10-Q view ·
4 2026-05-06 FORM 4 view ·
4 2026-04-17 FORM 4 view ·
4 2026-04-08 FORM 4 view ·
8-K 2026-04-07 8-K view ·
4 2026-04-03 FORM 4 view ·
DEF 14A 2026-04-01 DEF 14A view ·
4 2026-03-31 FORM 4 view ·
8-K 2026-03-23 8-K view ·
4 2026-03-20 FORM 4 view ·
4 2026-03-05 FORM 4 view ·
4 2026-03-05 FORM 4 view ·
4 2026-02-27 FORM 4 view ·
4 2026-02-25 FORM 4 view ·
4 2026-02-25 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
10-K 2026-02-19 10-K view ·
8-K 2026-02-19 8-K view ·
4 2026-02-11 FORM 4 view ·
4 2026-02-11 FORM 4 view ·
4 2026-02-06 FORM 4 view ·
4 2026-02-04 FORM 4 view ·
4 2026-02-04 FORM 4 view ·
4 2026-02-04 FORM 4 view ·
4 2026-02-04 FORM 4 view ·
4 2026-02-04 FORM 4 view ·
4 2026-01-22 FORM 4 view ·
4 2026-01-13 FORM 4 view ·
4 2026-01-13 FORM 4 view ·
8-K 2026-01-09 8-K view ·
4 2026-01-08 FORM 4 view ·
4 2026-01-08 FORM 4 view ·
4 2026-01-08 FORM 4 view ·
4 2026-01-08 FORM 4 view ·
4 2026-01-08 FORM 4 view ·
4 2026-01-06 FORM 4 view ·
4 2026-01-06 FORM 4 view ·
4 2026-01-06 FORM 4 view ·
4 2026-01-06 FORM 4 view ·
4 2026-01-06 FORM 4 view ·
4 2026-01-06 FORM 4 view ·
4 2025-12-19 FORM 4 view ·
8-K 2025-12-17 8-K view ·
4 2025-12-09 FORM 4 view ·

About

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 cl…